Investigating how circadian rhythms affect liver cancer in obesity.
Sympathetic circadian dysfunction in obesity-related hepatocarcinogenesis
['FUNDING_R01'] · BAYLOR COLLEGE OF MEDICINE · NIH-10685480
This study is looking at how problems with our body's natural clock might lead to liver cancer in people who are overweight, and it will also test if a common heart medication can help prevent this cancer in those with liver issues related to obesity.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BAYLOR COLLEGE OF MEDICINE (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10685480 on ClinicalTrials.gov |
What this research studies
This research explores the connection between circadian dysfunction in the sympathetic nervous system and the development of liver cancer related to obesity. It aims to understand how disruptions in biological rhythms may contribute to liver disease and cancer, particularly focusing on non-alcoholic fatty liver disease (NAFLD). The study will also evaluate the potential of beta-blockers, a type of medication, to prevent liver cancer in patients with obesity-related liver conditions. By using animal models that mimic human obesity, the research seeks to uncover the underlying mechanisms of liver cancer development and treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are obese and at risk for non-alcoholic fatty liver disease or liver cancer.
Not a fit: Patients without obesity or those who do not have liver-related conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new prevention and treatment strategies for liver cancer in obese patients.
How similar studies have performed: Previous studies have indicated that targeting circadian rhythms and sympathetic nervous system dysfunction may be effective in cancer treatment, suggesting a promising avenue for this research.
Where this research is happening
HOUSTON, UNITED STATES
- BAYLOR COLLEGE OF MEDICINE — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FU, LONING NONE — BAYLOR COLLEGE OF MEDICINE
- Study coordinator: FU, LONING NONE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Drug, Neoplastic Disease Chemotherapeutic Agents, anti-cancer drug, anticancer agent